SEARCH

SEARCH BY CITATION

References

  • 1
    Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995; 22: 17141719.
  • 2
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 14131419.
  • 3
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134140.
  • 4
    Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450455.
  • 5
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 18441850.
  • 6
    Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 11551163.
  • 7
    Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001; 116: 263270.
  • 8
    Moirand R, Mendler MH, Guillygomarc'h A, Brissot P, Deugnier Y. Non-alcoholic steatohepatitis with iron: part of insulin resistance-associated hepatic iron overload? J Hepatol 2000; 33: 10241026.
  • 9
    Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003; 35: 172178.
  • 10
    Guillygomarc'h A, Mendler MH, Moirand R, Jouanolle AM, David V, Deugnier Y. HFE mutations in insulin resistance-associated hepatic iron overload. J Hepatol 2000; 33: 515516.
  • 11
    Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. HEPATOLOGY 2004; 39: 179187.
  • 12
    Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 35053516.
  • 13
    Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 24482455.
    Direct Link:
  • 14
    George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311318.
  • 15
    Fargion S, Bissoli F, Fracanzani AL, Suigo E, Sergi C, Taioli E, et al. No association between genetic hemochromatosis and alpha1-antitrypsin deficiency. HEPATOLOGY 1996; 24: 11611164.
  • 16
    Ferrarotti I, Baccheschi J, Zorzetto M, Tinelli C, Corda L, Balbi B, et al. Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency. J Med Genet 2005; 42: 282287.
  • 17
    Eigenbrodt ML, McCashland TM, Dy RM, Clark J, Galati J. Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease. Am J Gastroenterol 1997; 92: 602607.
  • 18
    Serfaty L, Chazouilleres O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chretien Y, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. HEPATOLOGY 1997; 26: 776779.
  • 19
    Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. HEPATOLOGY 1998; 28: 10581063.
  • 20
    Rabinovitz M, Gavaler JS, Kelly RH, Van Thiel DH. Association between heterozygous alpha 1-antitrypsin deficiency and genetic hemochromatosis. HEPATOLOGY 1992; 16: 145148.
  • 21
    Anand S, Schade RR, Bendetti C, Kelly R, Rabin BS, Krause J, et al. Idiopathic hemochromatosis and alpha-1-antitrypsin deficiency: coexistence in a family with progressive liver disease in the proband. HEPATOLOGY 1983; 3: 714718.
  • 22
    Fargion S, Sergi C, Bissoli F, Fracanzani AL, Suigo E, Carazzone A, et al. Lack of association between porphyria cutanea tarda and alpha 1-antitrypsin deficiency. Eur J Gastroenterol Hepatol 1996; 8: 387391.
  • 23
    Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 22252236.
  • 24
    Graziadei I, Kahler CM, Wiedermann CJ, Vogel W. The acute-phase protein alpha 1-antitrypsin inhibits transferrin-receptor binding and proliferation of human skin fibroblasts. Biochim Biophys Acta 1998; 1401: 170176.
  • 25
    Graziadei I, Weiss G, Egger C, Niederwieser D, Patsch JR, Vogel W. Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein alpha1-antitrypsin. Exp Hematol 1998; 26: 10531060.
  • 26
    Graziadei I, Weiss G, Bohm A, Werner-Felmayer G, Vogel W. Unidirectional upregulation of the synthesis of the major iron proteins, transferrin-receptor and ferritin, in HepG2 cells by the acute-phase protein alpha1-antitrypsin. J Hepatol 1997; 27: 716725.
  • 27
    Weiss G, Graziadel I, Urbanek M, Grunewald K, Vogel W. Divergent effects of alpha 1-antitrypsin on the regulation of iron metabolism in human erythroleukaemic (K562) and myelomonocytic (THP-1) cells. Biochem J 1996; 319: 897902.
  • 28
    Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274280.
  • 29
    Deugnier YM, Loreal O, Turlin B, Guyader D, Jouanolle H, Moirand R, et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992; 102: 20502059.
  • 30
    Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N Engl J Med 2004; 350: 23832397.
  • 31
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 32
    Braun A, Meyer P, Cleve H, Roscher AA. Rapid and simple diagnosis of the two common alpha 1-proteinase inhibitor deficiency alleles Pi*Z and Pi*S by DNA analysis. Eur J Clin Chem Clin Biochem 1996; 34: 761764.
  • 33
    Zuntar I, Topic E, Jurcic Z, Zubcic A. Genotyping of alpha-antitrypsin in ten Croatian families. Clin Biochem 2000; 33: 377382.
  • 34
    Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 17691778.
  • 35
    Laine F, Jouannolle AM, Morcet J, Brigand A, Pouchard M, Lafraise B, et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 2005; 43: 10551059.
  • 36
    Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 14671476.
  • 37
    Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005; 129: 19371943.
  • 38
    Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005; 106: 37103717.